Gremlin and renal diseases: ready to jump the fence to clinical utility?. Issue 5 (8th July 2017)

• Record Type: Journal Article
• Authors: Mezzano, Sergio; Droguett, Alejandra; Lavoz, Carolina; Krall, Paola; Egido, Jesús; Ruiz-Ortega, Marta
• Is Part Of: Nephrology dialysis transplantation. Volume 33:Issue 5(2018)
• Page Start: 735
• Page End: 741
• Publication Date: 2017-07-08
• Subjects: diabetic nephropathy -- fibrosis -- Gremlin -- inflammation -- TGF-β1 -- VEGF; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfx194
• Languages: English
• ISSNs: 0931-0509

Abstract

ABSTRACT: The current therapeutic strategy for the treatment of chronic kidney diseases only ameliorates disease progression. During renal injury, developmental genes are re-expressed and could be potential therapeutic targets. Among those genes reactivated in the adult damaged kidney, Gremlin is of particular relevance since recent data suggest that it could be a mediator of diabetic nephropathy and other progressive renal diseases. Earlier studies have shown that Gremlin is upregulated in trans-differentiated renal proximal tubular cells and in several chronic kidney diseases associated with fibrosis. However, not much was known about the mechanisms by which Gremlin acts in renal pathophysiology. The role of Gremlin as a bone morphogenetic protein antagonist has clearly been demonstrated in organogenesis and in fibrotic-related disorders. Gremlin binds to vascular endothelial growth factor receptor 2 (VEGFR2) in endothelial and tubular epithelial cells. Activation of the Gremlin–VEGFR2 axis was found in several human nephropathies. We have recently described that Gremlin activates the VEGFR2 signaling pathway in the kidney, eliciting a downstream mechanism linked to renal inflammatory response. Gremlin deletion improves experimental renal damage, diminishing fibrosis. Overall, the available data identify the Gremlin–VEGFR2 axis as a novel therapeutic target for kidney inflammation and fibrosis and provide a rationale for unveiling new concepts to investigate in several clinical conditions.